Skip the wait and schedule your appointments online or through MyChart.

RSV (Respiratory Syncytial Virus) season: What parents need to know

Research & Innovation

Melanoma Clinical Trials

Clinical Trials

ECOG-ACRIN EA6194 ClinicalTrials.gov identifier NCT04708418

Physician & Study Coordinator

Study Coordinator

Amy Grossman, RN
484-658-1788

Amy.grossman@sluhn.org

Close

Synopsis

Synopsis: This phase II trial studies the effect of pembrolizumab alone or in combination with CMP-001 in treating patients with melanoma that can be treated by surgery (operable). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunotherapy with CMP-001 may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. The addition of CMP-001 to pembrolizumab could improve the ability of the immune system to shrink tumors and to prevent them from returning.

Close

Eligibility Criteria

>= 18 years old

Diagnosis of melanoma by AJCC 8th edition:

  • T0, TX or T1-4 and
  • N2b, N2C, N3b or N3c

Patients may have a presentation with primary melanoma with concurrent regional nodal and/or in-transit metastasis; or patients may have a history of primary melanoma or unknown primary melanoma presenting with clinically detected regional nodal and/or in-transit recurrence; and may belong to any of the following groups:

  • Primary cutaneous melanoma with clinically apparent regional lymph node metastases and/or in-transit metastases
  • Clinically detected recurrent melanoma at the proximal regional lymph node(s) basin
  • Primary cutaneous melanoma with concurrent nodal disease involving a single regional nodal group
  • Clinically detected nodal melanoma (if single site) arising from an unknown primary
  • In-transit cutaneous metastases with or without regional lymph node involvement permitted if considered potentially surgically resectable at baseline

Mucosal and uveal melanoma are excluded

Patients must be a candidate for definitive surgery and have met with the treating surgical oncologist prior to entry on study

Patients must have injectable and measurable disease

No prior systemic therapy for melanoma including immunotherapy and BRAF/MEK inhibitors and/or TLR-9 agonist

Close

SWOG 2015 (MelMarT-II)

Melanoma Margins Trial (MelMarT): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma (NCT 03860883)

Physician & Study Coordinator

Study Coordinator

Amy Grossman, RN
484-658-1788

Amy.grossman@sluhn.org

Close

Synopsis

Synopsis: This study will determine whether there is a difference in disease free survival for patients treated with either a 1cm excision margin or 2cm margin for clinical stage II (pT2b-pT4b) primary cutaneous melanoma.

Close

Eligibility Criteria
  • Patients must have stage II primary invasive cutaneous melanoma (including head, neck, truck, extremity, scalp, palm or sole) with Breslow thickness >2mm without ulceration, or >1mm with ulceration (pT2b-pT4b, AJCC 8th edition) as determined by diagnostic biopsy and subsequent histopathological analysis
  • An uninterrupted 2cm margin must be technically feasible around biopsy scar or primary melanoma
  • Surgery (which refers to the staging sentinel node biopsy and wide local excision as these are both to be done on the same day) must be completed within 120 days of the original diagnosis
  • Patients must have an ECOG PS of 0 or 1
  • Patients may not have uncertain diagnosis of melanoma, i.e. 'melanocytic lesion of unknown malignant potential
  • Patients who have undergone WLE at the site of primary index lesion, are unable or ineligible to undergo staging SLNB, or have a history of previous or concurrent invasive melanoma are excluded- Patients must not have physical, clinical, radiographic or pathologic evidence of satellite, in-transit, regional or distant metastatic melanoma
  • Subungual, pure desmoplastic or neurotropic, mucosal, uveal melanomas are excluded. The cutaneous lesion may not be located distal to the metacarpophalangeal joint, on the tip of the nose, the eyelids or on the ear
  • Planned adjuvant radiotherapy to the primary melanoma after WLE is not permitted

Close